Novel glycan therapeutic to treat ards
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2210093
- Recipient
-
IHP Therapeutics Inc. UEI MASZJLS7DHK3
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $217,928
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Originally
- Place of performance
- San Carlos, CA 94070, USA
Award details come from USAspending.gov.
About this award
IHP Therapeutics Inc. was awarded a $217,928 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from March 2022 through September 2023 to develop a novel glycan therapeutic to treat Acute Respiratory Distress Syndrome. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research solutions. This award seeks to advance that objective by investigating a new glycoprotein treatment for ARDS, a life-threatening lung condition that commonly affects soldiers on the battlefield. The sub-awardee, located in San Carlos, CA, will leverage the funding to develop this medical solution over the 18-month period of performance.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $217,928 |
Quick answers
Who received award W81XWH2210093?
W81XWH2210093 was awarded to IHP Therapeutics Inc. by Medical Command (Department of the Army) on March 15, 2022.
How much is award W81XWH2210093 worth?
$217,928 has been obligated on W81XWH2210093.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award